Getting to Yes: How Deal-Making Fuels Biotech Growth – 2025 Updates
biotech dealmaking; mergers and acquisitions; licensing; venture capital; BATNA; pharmaceutical negotiations; reputation; pipeline gaps; patent cliffs; valuation; regulatory uncertainty
Rising Pharmaceuticals Lowers Headcount After Closing Decatur Factories
Rising Pharmaceuticals; factory closure; Decatur Illinois; layoffs; pharma industry; WARN notice; 2025
Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate
Glenmark; Hengrui Pharma; Trastuzumab Rezetecan; HER2-targeting antibody drug conjugate; oncology; exclusive license; $1.1 billion deal; cancer therapy; milestone payments; royalties
Acadia Pulls Plug on Prader-Willi Drug After Phase 3 Trial Failure
Acadia Pharmaceuticals; Prader-Willi syndrome; carbetocin; ACP-101; phase 3 trial; hyperphagia; clinical trial failure; Soleno Therapeutics; Vykat XR
Placebo Response Trips Up Harmony Biosciences’ Fragile X Drug in Late-Stage Phase 3 Trial
Harmony Biosciences; ZYN002; Fragile X syndrome; Phase 3 trial; placebo response; clinical trial failure; RECONNECT study; transdermal cannabidiol gel
Sparrow Pharmaceuticals Raises $95M Series B for Midstage Diabetes Study
Sparrow Pharmaceuticals; Series B fundraising; Type 2 diabetes; clofutriben; phase 2b trial; HSD-1 inhibition; cortisol; RA Capital Management; Forbion; venture capital
uniQure’s Gene Therapy AMT-130 Significantly Slows Huntington’s Progression in Pivotal Trial
Gene therapy; uniQure; AMT-130; Huntington’s disease; clinical trial; disease progression; FDA approval; huntingtin-lowering; neurodegeneration
Acadia Halts Development of Nasal Prader-Willi Drug After Phase 3 Failure
Acadia Pharmaceuticals; carbetocin; Prader-Willi syndrome; Phase 3 trial; COMPASS PWS study; clinical trial failure; nasal spray; hyperphagia
Biogen Plans Resubmission After FDA Declines High-Dose Spinraza for SMA, Requests More Production Information
Biogen; Spinraza; nusinersen; high dose; FDA; Complete Response Letter; spinal muscular atrophy; SMA; supplemental New Drug Application; Chemistry Manufacturing and Controls; CMC; regulatory; resubmission
Sanofi Injects $625M Into Biotech Investment Arm to Accelerate Innovation
Sanofi; Sanofi Ventures; biotech investment; $625M cash infusion; digital health; immunology; rare diseases; neurology; venture capital; cell/gene therapy; portfolio expansion